# Efficacy and Safety Study of HS-10542 for IgA Nephropathy

> **NCT07474636** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- IgAN
- Immunoglobulin A Nephropathy (IgAN)
- Glomerular Disease

## Interventions

- **DRUG:** HS-10542 High Dose
- **DRUG:** HS-10542 Low Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07474636
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-01-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07474636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07474636, "Efficacy and Safety Study of HS-10542 for IgA Nephropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07474636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*